ARTICLE | Clinical News
TH-302: Phase I/II data
June 1, 2009 7:00 AM UTC
Interim data from 30 evaluable patients in the dose-escalation Phase I part of the U.S. Phase I/II TH-CR-402 trial showed that 240-480 mg/m 2 weekly IV TH-302 in combination with one of Gemzar, Alim...